The Binding Site's Freelite approved in Japan
This article was originally published in Clinica
Executive Summary
The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved The Binding Site's Freelite assay. The test is used to detect and monitor multiple myeloma (MM) and related plasma cell disorders. Freelite measures levels of free light chains (molecular components of immunoglobulins) in serum, which are higher in patients with MM. Levels drop if a patient is responding well to treatment. Freelite has been approved in the US for diagnosing MM since 2001 and Birmingham, UK-based The Binding Site also markets the test in Europe. Meanwhile, the US National Comprehensive Cancer Network has recommended Freelite in its latest guidelines for the initial diagnostic workup of MM and related disorders.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.